Johnson & Johnson Family of Companies
NEWS
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
Pfizer announced plans to create a professional services office in Tampa, Florida. It will be located in more than 100,000 square feet of office space and believe they will be generating hundreds of new jobs.
A manufacturing mistake at Emergent Biosolutions ruined a 15 million-dose batch of Johnson & Johnson’s Vaxzevria in production.
As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.
This morning, Janssen announced Ponvory has been greenlit as the only oral disease-modifying therapy studied against an established oral comparator for this indication.
Long-term data from Janssen’s Phase III DISCOVER-2a trial show that TREMFYA® (guselkumab), a selective IL-23 inhibitor, lead to skin clearance and joint symptom relief for up to two years in patients with active psoriatic arthritis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
JOBS
IN THE PRESS